期刊文献+

双特异性抗体潜在临床应用的研究进展 被引量:2

Reasearch progress of bispecific antibodies in potential clinical applications
暂未订购
导出
摘要 双特异性抗体(bispecific antibody,BsAb)是具有两个抗原结合位点,可选择性募集效应细胞到靶细胞周围,介导特异性杀伤作用的新型抗体。BsAb由两条不同的重链和轻链组成,可分别结合到呈现不同细胞类型的两个抗原上(靶细胞表面抗原,载荷物如效应细胞)。近年来,随着国内外BsAb的相关研究的飞速发展,因BsAb在疾病诊治中的作用逐渐丰富而受到广泛关注。本文就BsAb的临床应用及研究新进展作一综述。 The bispecific antibody is a novel antibody,which has 2 antigen binding sites,and it can mediate specific killing effect by selectively raising the effector cells to the surrounding of target cells.BsAb is composed of 2 different chains: the heavy chain and the light chain,which can bind to 2 antigens showed different cell types respectively(target cell surface antigen,load such as effector cells).With the rapid development of research at home and abroad in recent years,BsAb was gradually attracted widespread attention to its use in diagnosis and treatment.The clinical applications and new development of BsAb were reviewed in this paper.
机构地区 解放军第
出处 《胃肠病学和肝病学杂志》 CAS 2012年第10期971-974,共4页 Chinese Journal of Gastroenterology and Hepatology
关键词 双特异性抗体 肿瘤治疗 免疫性疾病 干细胞移植 Bispecific antibody Cancer treatment Autoimmune diseases PET Stem cell transplantation
  • 相关文献

参考文献31

  • 1Lure LG, Davol PA, Lee RJ, et a|. The new face of bispecific antibod- ies: targeting cancer and much more [ J]. Exp Hematol, 2006, 34 (1): 1-6.
  • 2Verneris MR, Arshi A, Edinger M, et al. Low levels of Her2/neu ex- pressed by Ewing' s family tumor cell lines can redirect eytokine-in- duced killer cells [ J]. Clin Cancer Res, 2005, 11 (12) : 4561-4570.
  • 3Chan JK, Hamilton CA, Cheung MK, et al. Enhanced killing of pri- mary ovarian cancer by retargeting autologous cytokine-induced killer ceils with bispecific antibodies: a preclinical study [ J]. Clin Cancer Res, 2006, 12(6) : 1859-1867.
  • 4Morecki S, Lindhofer H, Yacovlev E, et al. Induction of long-lasting antitumor immunity by concomitant cell therapy with allogeneic lympho- cytes and trifunctional bispecific antibody [ J]. Exp Hematol, 2008, 36(8) : 997-1003.
  • 5Cioffi M, Dorado J, Baeuerle PA, et al. EpCAM/CD3-Bispecific T-cell engaging antibody MTllO eliminates primary human pancreatic cancer stem cells [J]. Clin Cancer Res, 2012, 18(2) : 465-474.
  • 6Stanglmaier M, Faltin M, Ruf P, et al. Bi20 (fBTA05) , a novel tri- functional bispecific antibody ( anti-CD20 x anti-CD3 ), mediates effi- cient killing of B-cell lymphoma ceils even with very low CD20 expres- sion levels [J]. Int J Cancer, 2008, 123(5): 1181-1189.
  • 7Thakur A, Sorenson C, Norkina O, et al. Activated T cells from um- bilical cord blood armed with anti-CD3 x anti-CD20 bispecific anti- body mediate specific cytotoxicity against CD20 + targets with minimal allogeneic reactivity: a strategy for providing antitumor effects after cord blood transplants [J]. Transfusion, 2012, 52(1 ) : 63-75.
  • 8d' Argouges S, Wissing S, Brandl C, et al. Combination of rituximab with blinatumomab ( MTlO3/MEDI-538 ), a T cell-engaging CDI9-/ CD3-bispecific antibody, for highly efficient lysis of human B lympho- macells [J]. LeukRes, 2009, 33(3): 465-473.
  • 9Gautherot E, Bouhou J, Le Doussal JM, et al. Therapy for colon carci- noma xenografts with bispecific antibody-targeted, iodine-131-1abeled bivalent hapten [J]. Cancer, 1997, 80(12 Suppl):2618-2623.
  • 10Azria D, Dorvillius M, Gourgou S, et al. Enhancement of radiation therapy by tumor necrosis factor alpha in human colon cancer using a bispecific antibody [ J]. Int J Radiat Oncol Biol Phys, 2003, 55 (5) : 1363-1373.

二级参考文献26

  • 1杨进强,李勇,赵群,陈少轩,邝钢,范立侨,宋振川,赵雪峰,王冬.CIK细胞对裸鼠腹膜移植人胃癌细胞增殖和凋亡影响的实验研究[J].肿瘤防治杂志,2005,12(6):425-428. 被引量:8
  • 2蒋敬庭,吴昌平,邓海峰,陆明洋,李敏,王赫,吴骏.细胞因子诱导的杀伤细胞与肿瘤浸润淋巴细胞体外细胞毒活性比较[J].检验医学,2005,20(4):322-324. 被引量:18
  • 3Chen Y, Yang SC, Luo H. A chermira antibody erythroimmunoassay for detecting HBsAg in human sera [J]. Res Virol, 1990, 141 (3) : 337-339.
  • 4Grimm E, Bonavida B. Mechenism of cell mediated cytotoxicity at the single cell level [J]. J Immunol, 1979, 123(6) : 2861-2869.
  • 5Wells A. EGF receptor [J]. Int J Biochem Cell Biol, 1999, 31(6) : 637 -643.
  • 6Reiter JL, Maihle NJ. A 1.8 aleration transcript form the human epidermal groth factor gene encodes a truncated form of the receptor [ J]. Nucleic Acids Res, 1996, 24(20) : 4050-4056.
  • 7Baselga J. Why the epidermal growth factor receptor? The rational for cancer therapy [ J ]. Oncologist, 2002, 7 (4) : 2-8.
  • 8Herbst RS, langer CJ. Epidermal growth factor receptors as a target for cancer treatment: the emerging role of IMC-C225 in the treatment of lung and head and neck cancer [ J]. Semin Oncol, 2002, 29 (1) : 27- 36.
  • 9Valerie R, Mendslsohn J, Dmitrovsky E. The epidermal growth factor receptor and its ligind as therapeutic targets in human tumors [ J]. Cytokiue Growth Factor Rev, 1996, 7(2) : 133-141.
  • 10SchrnidtWolf IG, Leftcrova P, Mehta BA, et al. Phenotypic characterization and identification of effector cell recognition of cytokine induced killer cells [J]. Exp Hematol, 1993, 21(13): 1673-1679.

共引文献8

同被引文献20

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部